BIOPHARMA
By
Could Chai’s $70 Million OpenAI-Backed Funding Propel the Next Leap in AI-Engineered Drug Discovery Success?
Key Highlights Breakthrough Funding and Industry BackingThe Series A round brings Chai Discovery’s total capital to $100 million,…
How Will Eli Lilly’s New $220,000 sq ft Hyderabad Tech Hub and 1,500-Strong AI Workforce Transform Global Biopharma Innovation?
Key Highlights Strategic Digital Operations Hub Anchors Eli Lilly’s Global Innovation AmbitionsEli Lilly’s Hyderabad facility located in Gachibowli…
Is AbbVie’s $15.4 Billion Q2 Surge and Strategic External Innovation Pipeline Redefining Big Pharma’s AI-Driven Growth Playbook in 2025?
Key Highlights Strong Q2 Financial Performance and Guidance RaiseAbbVie reported Q2 2025 net revenues of $15.423 billion, up…
How Will METiS Technologies’ RMB 400 Million Series D Raise Accelerate Beijing’s AI-Powered Nanodelivery Revolution in Biopharma by 2027?
Key Highlights Strong Capital Infusion to Accelerate AI-Driven Nanotechnology DevelopmentThe recent RMB 400 million (~$57 million) financing round…
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Is Abbott’s Dissolving Stent Set to Transform Peripheral Artery Disease Treatment in Europe?
Key Highlights A Breakthrough in PAD TreatmentAbbott has received CE Mark approval in Europe for its Esprit™ BTK…
